ArticleProceedings of the National Academy of Sciences of the United States of America2018
Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
10.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Ubiquitin-proteasome system inFrontiers in medicine · 2024Pooled it
- Structure-Activity Relationship Study of Antimalarial Asparagine-Derived Proteasome Inhibitors.ACS omega · 2026Article
- Anticancer proteasome inhibitors are detrimental to the growth of Toxoplasma gondii in vitro.BMC research notes · 2026Article
- Trichomonas vaginalis Drug Targets and Their Role in Drug Discovery and Development.Pharmaceutical research · 2026Review
- Targeting protein-protein interactions in Plasmodium: from asexual replication to sexual development.Parasites & vectors · 2026Review
- Optimization of Species-Selective Reversible Proteasome Inhibitors for the Treatment of Malaria.Journal of medicinal chemistry · 2025Article
- A recombinant expression system for thebioRxiv : the preprint server for biology · 2025Article
- Enhancing schistosomiasis drug discovery approaches with optimized proteasome substrates.Protein science : a publication of the Protein Society · 2025Article
- Combating Malaria: Targeting the Ubiquitin-Proteasome System to Conquer Drug Resistance.Tropical medicine and infectious disease · 2025Review
- Towards next-generation treatment options to combat Plasmodium falciparum malaria.Nature reviews. Microbiology · 2025Review
- The essential genome ofScience (New York, N.Y.) · 2025Article
- Structural comparison of human and Plasmodium proteasome β5 subunits: informing selective inhibitor design for anti-malaria agents.Malaria journal · 2025Article
- Identification of potent and reversible piperidine carboxamides that are species-selective orally active proteasome inhibitors to treat malaria.Cell chemical biology · 2024Article
- A fast-acting inhibitor of blood-stagebioRxiv : the preprint server for biology · 2024Article
- Peptidic Boronic AcidJournal of medicinal chemistry · 2024Article
- Article
- Characterization of dabrafenib-induced drug insensitivity via cellular barcoding and collateral sensitivity to second-line therapeutics.Scientific reports · 2024Article
- The proteasome as a drug target for treatment of parasitic diseases.Advances in parasitology · 2024Review
- Structures revealing mechanisms of resistance and collateral sensitivity of Plasmodium falciparum to proteasome inhibitors.Nature communications · 2023Article
- Identification of covalent fragment inhibitors for Plasmodium falciparum UCHL3 with anti-malarial efficacy.Bioorganic & medicinal chemistry letters · 2023Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 10 institutions in 3 countries.
Laura A KirkmanDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, NY 10065; lak9015@med.cornell.edu cnathan@med.cornell.edu gal2005@med.cornell.edu.
Wenhu ZhanDepartment of Microbiology and Immunology, Weill Cornell Medicine, NY 10065.
Joseph VisoneDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, NY 10065.
Alexis DziedziechDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, NY 10065.
Pradeep K SinghChemical Core Facility, Department of Biochemistry, Weill Cornell Medicine, NY 10065.ORCID 0000-0002-3570-1005
Hao FanDepartment of Microbiology and Immunology, Weill Cornell Medicine, NY 10065.
Xinran TongDepartment of Microbiology and Immunology, Weill Cornell Medicine, NY 10065.
Igor BruzualDepartment of Research and Development, Portland Veterans Affairs Medical Center, Oregon Health and Science University, Portland, OR 97239.
Ryoma HaraTri-Institutional Therapeutics Discovery Institute, New York, NY 10065.
Masanori KawasakiTri-Institutional Therapeutics Discovery Institute, New York, NY 10065.
Toshihiro ImaedaTri-Institutional Therapeutics Discovery Institute, New York, NY 10065.
Rei OkamotoTri-Institutional Therapeutics Discovery Institute, New York, NY 10065.
Kenjiro SatoTri-Institutional Therapeutics Discovery Institute, New York, NY 10065.
Mayako MichinoTri-Institutional Therapeutics Discovery Institute, New York, NY 10065.
Elena Fernandez AlvaroDiseases of the Developing World (DDW), Tres Cantos Medicine Development Campus, GlaxoSmithKline, Severo Ochoa 2, 28760, Tres Cantos, Madrid, Spain.
Liselle F GuiangDepartment of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA 94901.
Laura SanzDiseases of the Developing World (DDW), Tres Cantos Medicine Development Campus, GlaxoSmithKline, Severo Ochoa 2, 28760, Tres Cantos, Madrid, Spain.
Daniel J MotaDepartment of Medicine, University of California, San Francisco, CA 94143.
Kavitha GovindasamyDepartment of Microbiology, Biochemistry and Molecular Genetics, Rutgers New Jersey Medical School, Newark, NJ 11201.
Rong WangNMR Analytical Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Yan LingDepartment of Microbiology and Immunology, Weill Cornell Medicine, NY 10065.
Patrick K TumwebazeInfectious Diseases Research Collaboration, Kampala, Uganda.
George SukenickNMR Analytical Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Lei ShiDepartment of Biophysics, Weill Cornell Medicine, NY 10065.
Jeremie VendomeSchrödinger, Inc., New York, NY 10036.
Purnima BhanotDepartment of Microbiology, Biochemistry and Molecular Genetics, Rutgers New Jersey Medical School, Newark, NJ 11201.
Philip J RosenthalDepartment of Medicine, University of California, San Francisco, CA 94143.
Kazuyoshi AsoTri-Institutional Therapeutics Discovery Institute, New York, NY 10065.
Michael A FoleyTri-Institutional Therapeutics Discovery Institute, New York, NY 10065.
Roland A CooperDepartment of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA 94901.
Bjorn KafsackDepartment of Microbiology and Immunology, Weill Cornell Medicine, NY 10065.
J Stone DoggettDepartment of Research and Development, Portland Veterans Affairs Medical Center, Oregon Health and Science University, Portland, OR 97239.
Carl F NathanDepartment of Microbiology and Immunology, Weill Cornell Medicine, NY 10065; lak9015@med.cornell.edu cnathan@med.cornell.edu gal2005@med.cornell.edu.
Gang LinDepartment of Microbiology and Immunology, Weill Cornell Medicine, NY 10065; lak9015@med.cornell.edu cnathan@med.cornell.edu gal2005@med.cornell.edu.
Cornell University · USTri-Institutional Therapeutics Discovery Institute · USDominican University of California · USGlaxoSmithKline (Spain) · ESMemorial Sloan Kettering Cancer Center · USOregon Health & Science University · USRutgers, The State University of New Jersey · USUniversity of California, San Francisco · USInfectious Diseases Research Collaboration · UGSchrodinger (United States) · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MResistance of Malaria Parasites to Artemisinin-Based TherapiesR01AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2009 to 2024
$8.4MSF BUILD: Enabling Students to Represent in ScienceTL4GM118986 · NIGMS · SAN FRANCISCO STATE UNIVERSITY · PI MARQUEZ-MAGANA, LETICIA MARIA, MORRIS, MEGHAN D · 2015 to 2022
$5.4MResistance of Malaria Parasites to Artemisinin-Based Combination TherapiesR56AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2008 to 2008
$618kNovel Inhibitors of Malaria ProteasomeR21AI123794 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI KIRKMAN, LAURA, LIN, GANG · 2017 to 2018
$466kSpecies selective dipeptide inhibitors for Mtb proteasomeR21AI101393 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI LIN, GANG · 2013 to 2014
$465kIdentification of the target of a compound that inhibits plasmodium sporozoitesR21AI094167 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI BHANOT, PURNIMA · 2012 to 2013
$436kDevelopment of the potent anti-malarial and anti-Toxoplasma drug, ELQ-316IK2BX002440 · VA · PORTLAND VA MEDICAL CENTER · PI DOGGETT, JOSEPH STONE · 2014 to 2018
–BLRD VA IK2 BX002440NCI NIH HHS P30 CA008748NIAID NIH HHS R01 AI075045NIAID NIH HHS R21 AI094167NIAID NIH HHS R21 AI101393NIAID NIH HHS R21 AI123794NIAID NIH HHS R56 AI075045NIGMS NIH HHS TL4 GM118986
Abstract
We describe noncovalent, reversible asparagine ethylenediamine (AsnEDA) inhibitors of the
Indexed as
AntimalarialsArtemisininsBortezomibDrug Resistance, MicrobialHumansLactonesOligopeptidesPlasmodium falciparumProteasome Endopeptidase ComplexProteasome InhibitorsProtozoan ProteinsAntimalarialsartemisinArtemisininsBortezomibcarfilzomibLactonesOligopeptidesProteasome Endopeptidase ComplexProteasome InhibitorsProtozoan Proteinsartemisinincollateral sensitivitymalariaPlasmodiumproteasome inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.